Myriad Genetics earnings release, May 5, 2026

Myriad Genetics Inc (MYGN) · Form 8-K, Item 2.02 · Filed · SEC filing

Myriad Genetics Reports First Quarter 2026 Financial Results;

Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Highl ights

• First quarter

2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.

• First quarter 2026 test volume reflects 13% and 7% test volume growth year-over-year in Cancer Care Continuum and Mental Health, respectively, offset by a 12% decline year-over-year in Prenatal Health test volume.

• Launched Precise Molecular Residual Disease (MRD), Myriad Genetics' ultrasensitive assay, representing progress toward earlier insight, more informed decisions, and better outcomes for cancer patients.

• Received FDA approval of the MyChoice CDx test as the companion diagnostic for Zejula®, for patients with advanced ovarian cancer.

• First quarter 2026 gross margin was 68.7%, up 20.0 basis points from the first quarter 2025.

• First quarter 2026 GAAP net loss of $34.1 million, or $0.36 per share, while adjusted loss per share was $0.09 per share and adjusted EBITDA was $(4.5) million.

SALT LAKE CITY, May 5, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its first quarter ended March 31, 2026, and reaffirmed its financial guidance for the full-year 2026.

"We are seeing strong performance across a number of key areas, including the Cancer Care Continuum as we begin to realize a return on our focused strategy. We have implemented a dedicated hereditary cancer sales force and other key programs designed to support the expected continued growth in germline testing. And with decisive steps taken to address our Prenatal Health business, we expect improved performance in the remainder of 2026,” said Sam Raha, President and CEO, Myriad Genetics. “Our limited launch of Precise MRD for breast cancer patients has received positive early feedback and we remain on track with our other planned launches in 2026, as part of our milestone-rich year. We are confident these tests will be important drivers of our growth in 2027 and beyond."¹

Financial and Operational Highlights

• Test volumes of 385,000 in the first quarter of 2026 were stable ye ar-over-year.

• The following table summarizes year-over-year testing volume changes in the company's core product categories:

• The following table summarizes year-over-year revenue changes in the company's core product categories:

Product Categories:

Cancer Care Continuum – MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, Precise Tumor, Precise MRD

Prenatal Health – Foresight, Prequel, FirstGene, SneakPeek

Mental Health – GeneSight

• Operating expenses in the first quarter of 2026 were $168.3 million, increasing $5.1 million year-over-year. Adjusted operating expenses in the first quarter of 2026 increased

$7.9 million year-over-year to $148.5 million, partially reflecting the company's progress in its multi-year investment program in key strategic areas.

• Operating loss in the first quarter of 2026 was $30.7 million.

Cash Flow and Liquidity

First quarter 2026 cash flow used in op erations was $15.7 million; adjusted operating cash outflow in the first quarter of 2026 was $13.4 million. Capital expenditures and capitalization of internal use software costs totaled $6.5 million in the first quarter 2026 resulting in adjusted free cash flow of $(19.9) million in the first quarter of 2026.

As of the end of the first quarter of 2026, the company had cash and cash equivalents of $124.4 million.²

Business Performance and Highlights

Cancer Care Continuum

The

Cancer Care Continuum business delivered revenue of $120.2 million in the first quarter of 2026.

• First quarter 2026 hereditary cancer testing revenue increased 5% year-over-year driven by a 14% year-over-year increase in volume.

• First quarter 2026 Prolaris testing revenue grew 3% year-over-year. The company continues to make progress on its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, and expects to launch the test in the second quarter of 2026.

• In April 2026, the company shared new data at a number of annual clinical society meetings, including the American Association for Cancer Research (AACR) and the Society of Gynecologic Oncology (SGO) underscoring Myriad Genetics' commitment to the Cancer Care Continuum and highlighting its progress in precision oncology. For example, data from one poster presentation showed that Precise MRD testing after adjuvant therapy for ovarian cancer is significantly prognostic of recurrence and that elevated risk was observed even at ctDNA levels detectable only by an ultrasensitive assay. The company believes this data reinforces the scientific strength behind the company's precision oncology programs and focus on advancing clinically meaningful innovations for patients and providers.

• In April 2026, Myriad Genetics received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the use of the MyChoice CDx test for prostate cancer patients as a companion diagnostic for Lynparza®(olaparib). With this approval, clinicians in Japan can now order the MyChoice CDx test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for breast and prostate cancers.

Prenatal Health

The Prenatal Health business delivered revenue of $41.9 million in the first quarter of 2026.

• Prenatal testing revenue in the first quarter of 2026 declined 15% year-over-year, as volume decreased 12% year-over-year reflecting a difficult year-over-year comparison as the company continues to engage with customers and address the disruption caused by the Q2 '25 implementation of the company's new order management system.

• ... (truncated) like the Company's Foresight Universal Plus test.

• The multi-site CONNECTOR study, using the company's FirstGene Multiple Prenatal Screen, continues to see progress in enrollment and the Company expects this study, if successful, to support future commercial launch activities and expand capabilities in prenatal testing.

Mental Health

GeneSight test revenue was $38.3 million in the first quarter of 2026.

• First quarter 2026 revenue grew 24% year-over-year reflecting 7% GeneSight volume growth, and overall improved reimbursement trends.³

Financial Guidance

Myriad Genetics does not provide forward-looking guidance in accordance with accounting principles generally accepted in the United States (GAAP) for the measures on which it provides forward-looking non-GAAP guidance as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, strategic realignment, costs related to amortization of intangibles from acquisitions, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the company's stock price. Any associated estimate of these items and their impact on GAAP performance could vary materially.

Below is a table summarizing Myriad Genetics' full-year 2026 financial guidance*:

Financial statements

Income Statement

2026 Guidance — Below is a table summarizing Myriad Genetics' full-year 2026 financial guidance*: (in millions, except percentages)

2026 Guidance
Adjusted Gross Margin %**68% - 69%
Revenue$860 - $880
Adjusted EBITDA***$37 - $49

Income Statement

Three months ended March 31, — (in millions, except per share amounts)

Three months ended March 31, – 20262025
Revenue200.4195.9
Cost of revenue62.861.7
Gross profit137.6134.2
Operating expenses:Research and development expense27.127.5
Operating expenses:Sales and marketing expense73.669.2
Operating expenses:General and administrative expense62.266.5
Operating expenses:Goodwill and long-lived asset impairment charges5.4
Operating expenses:Total operating expenses168.3163.2
Operating expenses:Operating loss-30.7-29
Other income (expense):Interest income0.70.3
Other income (expense):Interest expense-4.1-0.8
Other income (expense):Other0.1
Other income (expense):Total other expense-3.4-0.4
Other income (expense):Loss before income tax-34.1-29.4
Other income (expense):Income tax benefit29.3
Other income (expense):Net loss-34.1-0.1
Net loss per share:Basic and diluted-0.36
Weighted average shares outstanding:Basic and diluted93.791.4

Income Statement

Three months ended March 31, — (unaudited data in millions, except per share amounts)

Three months ended March 31, – 20262025
Adjusted Gross MarginGross Profit137.6134.2
Adjusted Gross MarginAcquisition - amortization of intangible assets(1)0.10.3
Adjusted Gross MarginEquity compensation(2)0.20.3
Adjusted Gross MarginOther adjustments(3)0.3
Adjusted Gross MarginAdjusted Gross Profit137.9135.1
Adjusted Gross Margin68.869
Adjusted Operating ExpensesOperating Expenses168.3163.2
Adjusted Operating ExpensesAcquisition - amortization of intangible assets(1)-6.4-8.8
Adjusted Operating ExpensesGoodwill and long-lived asset impairment(2)-5.4
Adjusted Operating ExpensesEquity compensation(3)-6.3-9.2
Adjusted Operating ExpensesReal estate optimization(4)-3
Adjusted Operating ExpensesStrategic realignment(5)-1.7-1.7
Adjusted Operating ExpensesOther adjustments(6)0.1
Adjusted Operating Expenses148.5140.6

Income Statement

Three months ended March 31, — (unaudited data in millions, except per share amounts)

Three months ended March 31, – 20262025
Adjusted EBITDANet Loss-34.1-0.1
Adjusted EBITDAAcquisition - amortization of intangible assets(1)6.59.1
Adjusted EBITDADepreciation expense(2)4.75.1
Adjusted EBITDAGoodwill and long-lived asset impairment(3)5.4
Adjusted EBITDAEquity compensation(4)6.59.5
Adjusted EBITDAReal estate optimization(5)3
Adjusted EBITDAStrategic realignment(6)1.71.7
Adjusted EBITDAInterest expense, net of interest income(7)3.40.5
Adjusted EBITDAOther adjustments(8)1.40.4
Adjusted EBITDAUncertain tax benefits(9)-28.7
Adjusted EBITDAIncome tax (benefit) expense(10)-0.6
Adjusted EBITDA-4.5-0.1

Balance Sheet

March 31, 2026 — (in millions, except per share amounts)

March 31, 2026December 31, 2025
Current assets:Cash and cash equivalents124.4149.6
Current assets:Trade accounts receivable123.8115.3
Current assets:Inventory27.930.6
Current assets:Prepaid taxes212
Current assets:Prepaid expenses and other current assets34.725.1
Current assets:Total current assets312.8332.6
Current assets:Operating lease right-of-use assets5149.4
Current assets:Property, plant and equipment, net111.5114
Current assets:Intangible assets, net145.7153.4
Current assets:Goodwill47.151.6
Current assets:Other assets5.65.6
Current assets:Total assets673.7706.6
Current liabilities:Accounts payable32.630
Current liabilities:Accrued liabilities90.596.9
Current liabilities:Current maturities of operating lease liabilities7.16.9
Current liabilities:Total current liabilities130.2133.8
Current liabilities:Long-term debt120.3119.9
Current liabilities:Noncurrent operating lease liabilities84.183
Current liabilities:Other long-term liabilities1.71.9
Current liabilities:Total liabilities336.3338.6
Stockholders’ equity:Common stock, 94.4 and 93.5 shares outstanding at March 31, 2026 and December 31, 2025, respectively0.90.9
Stockholders’ equity:Additional paid-in capital1,492.61,489
Stockholders’ equity:Accumulated other comprehensive income0.70.8
Stockholders’ equity:Accumulated deficit-1,156.8-1,122.7
Stockholders’ equity:Total stockholders' equity337.4368
Stockholders’ equity:Total liabilities and stockholders’ equity673.7706.6

Cash Flow

Three months ended March 31, — (in millions)

Three months ended March 31, – 20262025
Net cash used in operating activities-15.7-16.3
Net cash used in investing activities-6.5-8.3
Net cash provided by (used in) financing activities-313.6
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash-0.10.1
Net decrease in cash, cash equivalents, and restricted cash-25.3-10.9
Cash, cash equivalents, and restricted cash at beginning of the period151.3111.9
Cash, cash equivalents, and restricted cash at end of the period126101

Cash Flow

Three months ended March 31, — (unaudited data in millions, except per share amounts)

Three months ended March 31, – 20262025
Adjusted Operating and Free Cash FlowNet Cash Used in Operating Activities-15.7-16.3
Full release

These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release.

Conference Call and Webcast

A conference call will be held today, Tuesday, May 5, 2026, at 4:30 p.m. ET to discuss Myriad Genetics’ financial results and business developments for the first quarter of 2026. A live webcast of the conference call can be accessed on Myriad Genetics' Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register at https://register-conf.media-server.com/register/BI5f7c8739b7d5420b8a074eff2ce38a62. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. Following the conference call, an archived webcast of the call will be available at investor.myriad.com.⁴

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, MyChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Foresight Universal Plus, Precise Tumor, Precise Oncology Solutions, Precise Liquid, Precise MRD, FirstGene, SneakPeek, SneakPeek Early Gender DNA Test, SneakPeek Snap, Urosuite, myGeneHistory, Health.Illuminated., RiskScore, Prolaris, and GeneSight are registered trademarks or trademarks of Myriad Genetics, Inc. All third-party marks—® and™ —are the property of their respective owners.

© 2026 Myriad Genetics, Inc. All rights reserved.⁵

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (unaudited)

(in millions, except per share amounts)⁶

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (unaudited)

(in millions, except per share amounts)⁷

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (unaudited)

(in millions)⁸

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to (i) the company's full-year 2026 financial guidance, (ii) the company's programs designed to support the expected continued growth in germline testing as the company moves forward, (iii) the company's expectation of improved performance in the remainder of 2026, (iv) the company's expectation that it remains on track with its other planned launches in 2026, including its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, which the company expects to launch in the second quarter of 2026, and (v) the company's confidence that these tests will be important drivers of the company's growth in 2027 and beyond. These “forward-looking statements” are management’s present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.... (truncated) team and the successful implementation of the company's strategic plan; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for the company’s tests or the company’s ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests; the risk that the company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; the risk that the company is not able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms, if at all; the risk that the company may not successfully develop new markets or channels for its tests; the risk that licenses to the technology underlying the company’s tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the company’s laboratory testing facilities; risks related to public concern over genetic testing in general or the company’s tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the company’s ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; risks related to the company’s ability to successfully integrate and derive benefits from any technologies or businesses that it licenses, acquires or develops; risks related to the company’s projections or estimates about the potential market opportunity for the company’s current and future products; the risk that the company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the company’s tests; the risk of patent-infringement claims or challenges to the validity of the company’s patents; risks related to changes in intellectual property laws covering the company’s tests, or patents or enforcement, in the United States and foreign countries; risks related to security breaches, loss of data and other disruptions, including from cyberattacks and other cybersecurity incidents; risks of new, changing and competitive technologies in the United States and internationally and that the company may not be able to keep pace with the rapid technology changes in its industry, or properly leverage new technologies to achieve or sustain competitive advantages in its products; the risk that the company may be unable to comply with financial or operating covenants under the company’s credit or lending agreements; the risk that the company may not be able to maintain effective disclosure controls and procedures and internal control over financial reporting; risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of the company's insurance coverage limits and scope of insurance coverage with respect thereto; and other factors discussed under the heading “Risk Factors” contained in Part I, Item 1A of the company’s Annual Report on Form 10-K filed with the SEC on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. The company is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.⁹¹⁰

Statement Reg arding use of Non-GAAP Financial Measures

In this press release, the company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the company’s business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the schedules below and a description of the adjustments made to the GAAP financial measures is included at the end of each schedule.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, if available, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

The company does not forecast GAAP gross margin or GAAP net income (loss) because it cannot predict certain elements that are included in reported GAAP results. Please see above under “Financial Guidance” for a full explanation.¹¹

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025

(unaudited data in millions, except per share amounts)¹²¹³¹⁴¹⁵

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Myriad Genetics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.